FENOMA Study: Achieving Full Control in Patients with Severe Allergic Asthma

References

• Global Initiative for Asthma. Global strategy for asthma management and prevention 2019. Available from: https://ginasthma.org. Accessed 1018, 2019.
   Google Scholar
• Lotvall J, Akdis CA, Bacharier LB, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011;127:355–360. doi:10.1016/j.jaci.2010.11.03721281866
   PubMed Web of Science ®Google Scholar
• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:10.1183/09031936.0020201324337046
   PubMed Web of Science ®Google Scholar
• Murphy KR, Meltzer EO, Blaiss MS, Nathan RA, Stoloff SW, Doherty DE. Asthma management and control in the United States: results of the 2009 asthma insight and management survey. Allergy Asthma Proc. 2012;33(1):54–64. doi:10.2500/aap.2011.32.351822309716
   PubMed Web of Science ®Google Scholar
• Lombardi C, Savi E, Ridolo E, Passalacqua G, Canonica GW. Is allergic sensitization relevant in severe asthma? Which allergens may be culprit? World Allergy Organ J. 2017;10(1):2. doi:10.1186/s40413-016-0138-828101292
   PubMed Web of Science ®Google Scholar
• Antonicelli L, Bucca C, Neri M, et al. Asthma severity and medical resource utilisation. Eur Resp J. 2004;23(5):723–729. doi:10.1183/09031936.04.00004904
   PubMed Web of Science ®Google Scholar
• Palomares O, Sanchez-Ramon S, Davila I, et al. dIvergEnt: how IgE axis contributes to the continuum of allergic asthma and anti-IgE therapies. Int J Mol Sci. 2017;18:6. doi:10.3390/ijms18061328
   Web of Science ®Google Scholar
• Tabatabaian F, Ledford DK. Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history. J Asthma Allergy. 2018;11:53–61. doi:10.2147/JAA.S10798229662320
   PubMed Web of Science ®Google Scholar
• Corren J, Kavati A, Ortiz B, et al. Patient-reported outcomes in moderate-to-severe allergic asthmatics treated with omalizumab: a systematic literature review of randomized controlled trials. Curr Med Res Opin. 2018;34(1):65–80. doi:10.1080/03007995.2017.139573429057669
   PubMed Web of Science ®Google Scholar
• Xolair (Omalizumab). Summary of product characteristics. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/xolair. Accessed 1018, 2019..
   Google Scholar
• Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309–316. doi:10.1111/j.1398-9995.2004.00772.x15679715
   PubMed Web of Science ®Google Scholar
• Alhossan A, Lee CS, MacDonald K, Abraham I. “Real-life” effectiveness studies of omalizumab in adult patients with severe allergic asthma: meta-analysis. J Allergy Clin Immunol Pract. 2017;5(5):1362–1370 e2. doi:10.1016/j.jaip.2017.02.00228351783
   PubMed Web of Science ®Google Scholar
• MacDonald KM, Kavati A, Ortiz B, Alhossan A, Lee CS, Abraham I. Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008–2018. Expert Rev Clin Immunol. 2019;15(5):553–569. doi:10.1080/1744666X.2019.157457130763137
   PubMed Web of Science ®Google Scholar
• Campo Mozo P, Soto-Campos JG, Blanco Aparicio M, et al. Severe asthma phenotypes in patients controlled with omalizumab: a real-world study. Respir Med. 2019;159:105804. doi:10.1016/j.rmed.2019.10580431704593
   PubMed Web of Science ®Google Scholar
• Hanania NA, Wenzel S, Rosen K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804–811. doi:10.1164/rccm.201208-1414OC23471469
   PubMed Web of Science ®Google Scholar
• Executive Committee GEMA 2009. GEMA 2009 (Spanish guidelines on the management of asthma). J Investig Allergol Clin Immunol. 2010;20(Suppl 1):1–59.
   Google Scholar
• Juniper EF, O’Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14(4):902–907. doi:10.1034/j.1399-3003.1999.14d29.x10573240
   PubMed Web of Science ®Google Scholar
• Vega JM, Badia X, Badiola C, et al. Validation of the Spanish version of the Asthma Control Test (ACT). J Asthma. 2007;44(10):867–872. doi:10.1080/0277090070175261518097865
   PubMed Web of Science ®Google Scholar
• Cazzoletti L, Marcon A, Janson C, et al. Asthma control in Europe: a real-world evaluation based on an international population-based study. J Allergy Clin Immunol. 2007;120(6):1360–1367. doi:10.1016/j.jaci.2007.09.01917981317
   PubMed Web of Science ®Google Scholar
• de Marco R, Cazzoletti L, Cerveri I, et al. Are the asthma guideline goals achieved in daily practice? A population-based study on treatment adequacy and the control of asthma. Int Arch Allergy Immunol. 2005;138(3):225–234. doi:10.1159/00008872316210861
   PubMed Web of Science ®Google Scholar
• Mansur AH, Srivastava S, Mitchell V, Sullivan J, Kasujee I. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: study of efficacy and safety. Respir Med. 2017;124:36–43. doi:10.1016/j.rmed.2017.01.00828284319
   PubMed Web of Science ®Google Scholar
• Matucci A, Vultaggio A, Maggi E, Kasujee I. Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question? Respir Res. 2018;19(1):113. doi:10.1186/s12931-018-0813-029879991
   PubMed Web of Science ®Google Scholar
• Manga V, Humbert M, Djukanovic R, et al. Blood Eosinophils and serum IgE predict response to omalizumab in patients with severe allergic asthma: innovate trial post-hoc analysis. J Allergy Clin Immunol. 2016;137(2):AB16. doi:10.1016/j.jaci.2015.12.051
   Web of Science ®Google Scholar
• Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest. 2004;125(4):1378–1386. doi:10.1378/chest.125.4.137815078749
   PubMed Web of Science ®Google Scholar
• Humbert M, Taillé C, Mala L, Le Gros V, Just J, Molimard M. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Resp J. 2018;51(5):1702523. doi:10.1183/13993003.02523-2017
   PubMed Web of Science ®Google Scholar
• Casale TB, Luskin AT, Busse W, et al. Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study. J Allergy Clin Immunol Pract. 2019;7(1):156–164 e1. doi:10.1016/j.jaip.2018.04.04329800752
   PubMed Web of Science ®Google Scholar
• Papathanasiou E, Bakakos P, Hillas G, et al. Diagnostic accuracy of T2 biomarkers for the prediction of airway eosinophilia in treated smoking asthmatic patients with loss of asthma control. J Allergy Clin Immunol Pract. 2020;8(1):385–377.31257188
   PubMed Web of Science ®Google Scholar
• Buhl R, Humbert M, Bjermer L, et al. Severe eosinophilic asthma: a roadmap to consensus. Eur Respir J. 2017;49(5):1700634. doi:10.1183/13993003.00634-201728461308
   PubMed Web of Science ®Google Scholar